Navigation Links
Sinapis Pharma Announces Frederick Frank as Consultant

JACKSONVILLE, Fla., Sept. 8 /PRNewswire/ -- Sinapis Pharma, Inc is pleased to announce the addition of Frederick Frank as a consultant to the company. Mr. Frank will leverage his decades of experience to advise the company on merger and acquisition opportunities and fund raising for clinical trial development. Sinapis Pharma has discovered and is patenting a new therapeutic approach to treating stroke in humans using Methamphetamine in an intravenous (IV) formulation.

Mr. Frank will advise Sinapis on its M & A corporate development efforts to find a merger partner for Sinapis as the company conducts its Proof of Concept clinical trial. Sinapis is in discussions with potential pharma partners to form a collaboration that will provide Sinapis funding for its Phase I and IIA clinical trials, while granting the right to acquire Sinapis if the two trials are successful. Sinapis management estimates that the Phase IIA Proof of Concept clinical trial will be complete within approximately twenty-eight (28) months.

Mr. Frank is former Vice Chairman of Lehman Brothers where he spent thirty years building the premier big pharma and healthcare investment banking practice in the U.S. and Europe. Mr. Frank is the leading investment banker internationally for pharmaceutical company mergers, acquisitions and equity fund raising.

Sinapis Pharma, Inc ( is an early stage drug development company whose lead compound methamphetamine, as an intravenous infusion for the treatment of acute stroke and brain injury, has shown robust pre-clinical efficacy. It is a powerful neuroprotective agent with a remarkable 12 hour therapeutic window in animal studies of stroke. Sinapis CEO Donald Picker, Ph.D. states: "We are thrilled to have Fred Frank join our team at Sinapis. His creativity and depth of relationships in the pharmaceutical industry will be invaluable as we execute our development plan."

For more information contact Dr. Picker at

SOURCE Sinapis Pharma, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinapis Pharma To Present at Rodman & Renshaw Conference
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology: